News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trophos Awarded Key US Patent Covering Use of Novel Cardioprotective Compound, TRO40303


8/23/2011 9:55:31 AM

Marseille, France, August 23 2011 - Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack (myocardial infarction - MI).

The U.S. Patent, No. 7,985,774, is entitled "Use of 3,5-seco-4-nor-cholestane derivatives for obtaining a cytoprotective drug". This covers most notably inter alia cardiovascular indications, including the lead indication in clinical development of reducing cardiac ischemia-reperfusion injury. The patent also covers the use of TRO40303 and derivatives in treating a wide range of non-neurological degenerative diseases characterized by pathological cell death, and/or cell dysfunctions leading to cell death. These cell dysfunctions may for example be of mitochondrial origin such as a reduction in the capability of generating ATP, an incapability of capturing and/or retaining calcium, or the generation of free radicals.

“The granting of this key patent in the US by the USPTO is an important milestone for Trophos. TRO40303 will shortly enter a phase II proof-of-concept study to treat cardiac ischemia-reperfusion injury (IRI) in acute MI patients as part of an EU funded international translational medicine project, MitoCare, led by Trophos,” said Damian Marron, CEO at Trophos. “TRO40303’s potential in degenerative diseases was discovered using Trophos’ pioneering, proprietary screening assays and was characterized and developed by Trophos’ expert R&D teams in collaboration with leading external collaborators.”

A treatment is urgently required globally to prevent cardiac reperfusion injury, which is a major problem in the care of MI patients despite the overall improvements in prognosis in recent years. There is still no existing treatment for the problem that contributes to long-term morbidity, progression to heart failure and death following an MI. The role of mitochondrial permeability transition in cardiac reperfusion injury has recently been validated clinically. This creates a tremendous opportunity for Trophos’ novel mitochondrial pore modulator, TRO40303, both discovered and developed in the Trophos laboratories to target this mechanism. There are around 1.6 million cardiac reperfusion procedures performed in hospitals and specialist clinics each year in the western world alone.

The phase II proof-of-concept study of TRO40303 is to be sponsored by Trophos and performed as part of the EU funded MitoCare project (see below) by a consortium of prominent European clinical investigators, all of whom have extensive prior experience conducting and collaborating in large multi-centre clinical trials in cardiac IRI. The principal investigator will be professor Dan Atar from Oslo University Hospital, Norway. The study will be a placebo-controlled, phase II proof-of-concept study in acute MI patients with large myocardial infarct undergoing percutaneous transluminal coronary angioplasty (PTCA also known as coronary or balloon angioplasty) during percutaneous coronary intervention (PCI). TRO40303 will be administered as a single iv infusion prior to the reperfusion by angioplasty.

MitoCare is a two and a half year international, translational medicine project funded by a European Union award of EUR six million. MitoCare, which began in January 2011 (see release of December 14th 2010), is being conducted by a 16 partner consortium and led by Trophos. MitoCare forms part of the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (FP7). MitoCare will investigate the efficacy and safety of TRO40303 in a phase II proof-of-concept study to treat cardiac ischemia-reperfusion injury (IRI) in acute myocardial infarction (MI) patients and develop knowledge of biomarkers and models of cardiac ischemia-reperfusion injury.

About Trophos: http://www.trophos.com

Trophos is a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology. The Company has a novel and proprietary cholesterol oxime based chemistry platform generating a pipeline of drug candidates. The lead product, olesoxime (TRO19622), is in phase three development for the orphan neurological diseases of ALS (as part an EU funded project, MitoTarget) and spinal muscular atrophy (substantially funded by the AFM patient association). A second product, TRO40303, is in early clinical development to treat cardiac reperfusion injury (as part of an EU funded project, MitoCare). Trophos' mitochondrial pore modulator compounds enhance the function and survival of stressed cells via modulation of dysfunctional mitochondria through interactions at the permeability transition pore (mPTP). Recently published clinical studies support the therapeutic rationale for mitochondria targeted drugs, which Trophos is uniquely placed to exploit.

Trophos has two strategic partnership agreements with Actelion Ltd; an acquisition option agreement and a research collaboration agreement.

Trophos was founded in 1999, is based in Marseille, France and currently has 37 employees.

Mark Tidmarsh

ANDREW LLOYD & ASSOCIATES

http://www.ala.com

mark@ala.com

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND

Tel: +44 1273 675100

Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE

Tel: +33 1 56 54 07 00

Fax: +33 1 56 54 07 01

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION


Read at BioSpace.com

comments powered by Disqus
Trophos
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES